

ARS Pharmaceuticals (NASDAQ:SPRY) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been...
You can purchase shares of ARS Pharmaceuticals (NASDAQ:SPRY) through any online brokerage.
Other companies in ARS Pharmaceuticals’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
ARS Pharmaceuticals has a consensus price target of $27.50.
The stock price for ARS Pharmaceuticals (NASDAQ: SPRY) is $2.77 last updated November 5, 2026 at 7:06 PM EST.
There are no upcoming dividends for ARS Pharmaceuticals.
ARS Pharmaceuticals does not have any upcoming earnings scheduled.
There is no upcoming split for ARS Pharmaceuticals.
ARS Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free...